2.5 Budget impact analysis
intellectual disability
We projected 5-year undiscounted costs from the healthcare payer perspective, comparing incremental costs of the CB strategy over SOC to estimate the budget impact of providing CB to the entire eligible US population of children with ASD and without intellectual disability. We assumed 100% uptake of the intervention to estimate an upper bound of costs. To account for the potential that CB therapy has no significant impact, we additionally projected budgetary losses if a non-efficacious therapy is implemented.